share_log

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga ·  Nov 2 00:36

Gainers

  • Athira Pharma (NASDAQ:ATHA) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million.
  • ChromaDex (NASDAQ:CDXC) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday.
  • Theriva Biologics (AMEX:TOVX) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million.
  • GRI Bio (NASDAQ:GRI) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million.
  • Pro-Dex (NASDAQ:PDEX) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday.
  • Pediatrix Medical Group (NYSE:MD) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today.

Losers

  • Lexicon Pharmaceuticals (NASDAQ:LXRX) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million.
  • Autonomix Medical (NASDAQ:AMIX) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million.
  • Myriad Genetics (NASDAQ:MYGN) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion.
  • Pulse Biosciences (NASDAQ:PLSE) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago.
  • Biofrontera (NASDAQ:BFRI) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million.
  • Beyond Air (NASDAQ:XAIR) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment